Wuhan Puyuan Pharmaceutical

Wuhan Puyuan Pharmaceutical Co., Ltd. is a pharmaceutical company based in Wuhan, China, specializing in the research, development, and production of anti-tumor drugs and high-barrier complex formulations. Founded in 2018 as a subsidiary of Shenzhen Zifu Pharmaceutical, the company operates a modern manufacturing facility in the Wuhan East Lake High-tech Development Zone. Its product portfolio includes oncology-related treatments such as Amifostine and Incadronate Disodium, as well as hepatology products like Ursodeoxycholic acid tablets, for which it was the first to pass the consistency evaluation in China. Wuhan Puyuan Pharmaceutical leverages advanced technologies in semi-solid matrix formulations and sterile lyophilized preparations to provide high-quality therapeutic solutions. The company is an active participant in China's national drug procurement programs, demonstrating its strong commercial and manufacturing capabilities.